Novacyt Aktie

Novacyt EV/FCF

EV/FCF (Virksomhedsværdi til frit pengestrøm) for Novacyt (ALNOV.PA) pr. 24. aug. 2026 er -0,55. I foregående år var EV/FCF (Virksomhedsværdi til frit pengestrøm) 0,18 — en ændring på -416,08 % (lavere).

EV/FCF

-0,55

YoY

-416,08%

Senest opdateret:

EV/FCF (Virksomhedsværdi til frit pengestrøm) for Novacyt er 2026 -0,55 . EV/FCF (Virksomhedsværdi til frit pengestrøm) for Novacyt var 2025 0,18 . Det falder dermed med -416,08% lavere sammenlignet med året før.

Novacyt EV/FCF historik

  • 3 år

  • 10 år

  • 25 år

  • Maks

EV/FCF
Date
EV/FCF
1. jan. 2017
-4,93 GBP
1. jan. 2018
-16,74 GBP
1. jan. 2019
-28,04 GBP
1. jan. 2020
-0,63 GBP
1. jan. 2021
-6,46 GBP
1. jan. 2022
4,32 GBP
1. jan. 2023
0,18 GBP
1. jan. 2024
-0,55 GBP
Novacyt EV/FCF historik
ÅREV/FCFYoY
-0,55-416,08%
0,18-95,94%
4,32-166,85%
-6,46+921,58%
-0,63-97,75%
-28,04+67,51%
-16,74+239,36%
-4,93-52,87%
-10,47+141,70%
-4,33-51,72%
-8,97
Access this data via the Eulerpool API

Novacyt Aktieanalyse

Hvad laver Novacyt? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Novacyt aktie

EV/FCF (Virksomhedsværdi til frit pengestrøm) for Novacyt er -0,55 i 2026.

EV/FCF (Virksomhedsværdi til frit pengestrøm) for Novacyt ændrede sig fra 0,18 til -0,55, hvilket repræsenterer en ændring på -416,08 %. Værdien er lavere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af EV/FCF (Virksomhedsværdi til frit pengestrøm) Novacyt siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

EV/FCF-forholdet måler virksomhedsværdien i forhold til frit pengestrøm og afspejler en virksomheds sande evne til at generere kontanter.

For at evaluere EV/FCF (Virksomhedsværdi til frit pengestrøm)s er det afgørende at sammenligne det med andre virksomheder i samme branche og sektor. På Eulerpool kan du finde branchsammenligninger for EV/FCF (Virksomhedsværdi til frit pengestrøm).

En 'god' varierer efter branche og virksomhedens udviklingsstadium. På Eulerpool kan du sammenligne EV/FCF (Virksomhedsværdi til frit pengestrøm)s Novacyt med konkurrenter og branchegjennemsnittet for at afgøre, om den er attraktiv.

Access this data via the Eulerpool API

Værdiansættelse — Novacyt

Alle nøgletal — Novacyt